Bh

Periodontal disease is a common oral health issue that can silently worsen, causing gum inflammation, tooth loss, and reduced quality of life if not detected early. This research aims to evaluate how accurately an online self-assessment tool can identify periodontal risk among adults by comparing questionnaire results with clinical periodontal examinations. The study focuses on adults in the general population and seeks to improve early detection and preventive care for periodontal disease. Participants will complete an online questionnaire about their oral health symptoms, dental history, oral hygiene habits, and other relevant factors. They will also undergo a clinical periodontal examination during the same visit, performed by a trained clinician. The clinical exam will categorize participants into low, medium, or high periodontal risk groups, serving as the reference standard to assess the questionnaires accuracy. No treatment or preventive intervention is given as part of this observational study. During the study visit, participants will fill out the online questionnaire and receive the clinical examination. Researchers will measure how well the questionnaire-based risk categories agree with the clinical findings using diagnostic accuracy methods, including sensitivity, specificity, and agreement statistics. Minimal risks include mild discomfort or minor bleeding during the exam and privacy considerations. Participants data will be securely stored with identifiers to protect confidentiality. The study results aim to support improving the self-assessment tool for better community-level oral health prevention.

This research aims to collect long-term data on patients with generalized myasthenia gravis gMG who are prescribed Alexion complement C5 inhibition therapies, including eculizumab Soliris and ravulizumab Ultomiris. It is an observational, multinational registry designed to monitor clinical outcomes and safety over time in a real-world setting. The study is led by Alexion Pharmaceuticals, Inc. and involves multiple centers worldwide. Participants who join the registry will have their medical history and gMG treatment history reviewed retrospectively at enrollment. After joining, data will be gathered prospectively during routine clinical care visits and through patient-reported outcomes, all collected electronically. The registry maintains observation and data collection for up to five years from the day of enrollment. During the study, participants will be asked to attend routine visits where their clinical status, including the Myasthenia Gravis Activities of Daily Living MG-ADL score, will be assessed. Researchers will track changes in these scores approximately five years after enrollment to understand long-term outcomes. The study does not involve any experimental treatments but monitors patients receiving prescribed Alexion therapies as part of their usual care.

Chronic Obstructive Pulmonary Disease COPD is a major global health issue, leading to high morbidity and mortality, especially in low- and middle-income countries. Frequent exacerbations worsen the disease and increase death risk. Current guidelines recommend triple inhaled therapy combining an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-agonist for patients with persistent symptoms. BreztriTrixeo BGF is one such therapy approved based on controlled clinical trials, but real-world data on its effectiveness and patient experience is needed. This observational study, called iCHOROS, will follow adults with moderate to severe COPD treated with BGF in routine clinical settings across Latin America, Asia, and the Middle East & Africa. Participants will be observed for 12 months after starting BGF, with assessments at baseline, 12, 26, and 52 weeks. The study collects clinical data and patient-reported outcomes without altering the standard care or providing study medication, focusing on real-life use and effects of BGF. Participants will have their COPD status, symptom scores, lung function, exacerbation history, and treatment satisfaction recorded during scheduled visits. The main measure is the change in COPD Assessment Test CAT score after 12 weeks. Additional measures include exacerbation rates, dyspnea severity, spirometry, and patient satisfaction with inhalers. The study aims to provide insights into BGFs impact in diverse populations over one year of follow-up.